This application is directed to systems and methods for implanting devices in human hearts from a catheter approach.
Catheters are in widespread use for a wide number of procedures. In recent years, complex devices such as aortic valves have been delivered using catheters. These catheter based procedures provide benefits for patients, including reduced trauma compared to surgical techniques for accomplishing similar outcomes, e.g., aortic valve replacement.
Limitations of catheter based techniques have spurred efforts to develop a less invasive surgical technique that can be performed through cannulae inserted into the heart through the chest wall. These procedures have advantages, such as moving the proximal end of the tools used to perform the procedure closer to the surgical site.
Various downsides remain, however. For one, access to the heart through the chest wall is more complex than access to a superficial peripheral vessel, such as a femoral artery. For example, a surgical window must still be opened to advance the surgical cannulae through the skin and intervening tissue to the heart. The outside surface of the heart is a convex and tough structure that may not be easy to pierce from the outside surface. Thus, the chest wall access site may need to be enlarged, taking away the benefits of small cannulae.
Among the realizations described herein is the notion that catheter-based heart procedures can be greatly expanded by providing a delivery system that can be advanced from superficial peripheral vessels to the heart and through the heart wall to provide a taut delivery platform (sometimes called a “rail” herein) over which to deliver tools for preparing an implant site and a variety of implants.
In one embodiment, a method of placing a cardiac device in a heart of a patient is provided. Vascular access is provided at a peripheral superficial venous blood vessel. An access catheter is advanced through the peripheral superficial venous blood vessel, through the vena cava into the heart. A distal portion of the access catheter is advanced across the intra-atrial septum into the left atrium. A proximal portion of a delivery platform is advanced out of the access catheter to a position superior of the mitral valve opening. A distal portion of the delivery platform is advanced into the left ventricle and through the heart wall. A procedure zone of the delivery platform between the distal portion and the proximal portion is tensioned. The procedure zone extends at least from superior to the mitral valve to inferior of the mitral valve.
In another embodiment a method of placing a cardiac device in a heart of a patient is provided. The method includes advancing a delivery system percutaneously from a peripheral blood vessel access site into a heart. The delivery system has an elongate member with an enlargeable device disposed at a distal portion thereof. The enlargeable device is anchored to a heart wall. The elongate member is tensioned. A procedure is performed along the elongate member. The elongate member is retracted proximally and out of the peripheral blood vessel access site.
In another embodiment, a delivery system for rapid placement of heart implants at a mitral valve is provided. The system includes a delivery platform and a heart valve implant catheter. The delivery system includes a tubular catheter body, a piercing member, and a delivery platform. The tubular catheter body is sufficiently long and flexible to be advanced from a peripheral blood vessel access site to an atrium of the heart. The piercing member is configured to be advanced from the tubular body to create a transapical channel from an internal apical portion of a ventricle to an outside heart wall. The delivery system includes an elongate tension member and an anchor member disposed on a distal portion of the elongate tension member. The enlargeable member is configured to be enlarged in a pericardial space of an intact chest wall to cover an area of the outside heart wall surrounding an opening of the transapical channel. At least the heart valve implant is separable from the delivery system such that the tension member and anchor can be removed while leaving the heart valve implant in place in the heart.
A delivery system for rapid placement of heart implants is provided that includes a delivery platform. The delivery system includes a tubular catheter body, a piercing member, and a delivery platform. The tubular catheter body is sufficiently long and flexible to be advanced from a peripheral blood vessel access site to an atrium of the heart. The piercing member is configured to create a transapical channel from an internal apical portion of a ventricle to an outside heart wall. The delivery system includes an elongate tension member and an enlargeable member disposed on a distal portion of the elongate tension member. The enlargeable member is configured to be enlarged in a pericardial space of an intact chest wall to cover an area of the outside heart wall surrounding an opening of the transapical channel. When tensioned, the tension member provides a stable zone for positioning a heart implant within the heart.
A more complete appreciation of the subject matter of this application and the various advantages thereof can be realized by reference to the following detailed description, in which reference is made to the accompanying drawings in which:
More detailed descriptions of various embodiments of catheter based transapical delivery systems, components and methods useful to treat patients are set forth below.
As discussed above, various maladies affect these and other major structures of the heart.
The catheter body 104 can be configured in any way suitable to be advanceable from a peripheral blood vessel to the right atrium of the heart. One way to reach the left atrium is to access a femoral vein or other peripheral blood vessel. The catheter body 104 can be advanced from the femoral vein to the vena cava, through the eustacian valve into the right atrium. The access path from the venous vasculature is relatively straight. The catheter body 104 can be formed with a rigid polymer such as polyethylene and it may be optionally reinforced by a braided structure so that it is fairly rigid to a bending force (discussed below).
Preferably a distal portion 112 of the catheter body 104 is configured to traverse a lateral path through the right atrium to the intra-atrial septum. The lateral path is generally transverse to the path that the catheter body 104 traverses to approach the eustacian valve from the inferior venous vasculature. The lateral path can be facilitated by pre-shaping the catheter body 104 so that the catheter body 104 has an L shape when the catheter body is unconstrained. The lateral path can extend transverse to the right atrium to the fossa ovalis. In one embodiment the distal end of the distal portion 112 is sufficiently rigid to proceed through the fossa ovalis in response to gentle advancement by the clinician of a proximal portion of the catheter body 104. In another embodiment, the system 100 includes an access sheath (not shown) and the catheter body 104 is advanced through the sheath into the left atrium. The access sheath may be positioned across the atrial septum prior to delivery of the distal portion 112 across the intra-atrial septum via the fossa ovalis.
In the illustrated embodiment, the delivery platform 108 includes an elongate slender catheter body that can be disposed through the native mitral valve space and downward to the left ventricular apex.
Preferably a piercing member 124 is provided in the delivery system 100 that facilitates placement of the delivery platform 112.
If it is desired to deliver the piercing member 124 over the wire 128, the elongate body 124A can be made hollow as in
The piercing member 124 and elongate body 124A scan take any suitable shape, but preferably are sufficiently stiff and/or sharp to advance through the myocardium to create a trasnapical channel TAC through the heart wall. The TAC extends from an internal opening in the internal apical portion of a ventricle to an external opening at an outside heart wall. The TAC is preferably very small but large enough to permit a blocking member (e.g., balloon) to be advanced from inside the LV to the outside of the LV in the pericardial space.
The delivery platform 108 is configured to be advanced from the catheter body 104 along the piercing member 124. The delivery platform 108 preferably includes a thin walled tubular body 140 that includes a distal port 144 and a blocking member 148 disposed just proximal to the distal port 144. The blocking member 148 can be any device that is able to expand in the pericardial space, as discussed below, to a transverse width that is sufficient to block the external opening of the TAC.
The blocking member 148 can be a device that expands without requiring an inflation medium to be delivered for expansion. For example, the member 148 can have a low profile state for delivery and an enlarged state after it is placed in the pericardial space. Nitinol or other shape memory material can be used. The shape memory material can be in several different configurations. In one configuration, the shape member is a stress-induced shape memory. A blocking member 148 formed of stress-induced shape memory material can be delivered in a compressed state if it is constrained from expansion in some manner, e.g., by an outer sheath. Retraction of the sheath can enable this sort of blocking member 148 to expand in the pericardial space by releasing the strain energy that is stored in the shape memory material. The sheath could be analogous to the sheath 170 discussed below.
In one technique, after the piercing member 124 is advanced through the myocardium to create the TAC, the tubular body 140 is advanced through the TAC. Such advancement can be along the elongate body 124A proximal of the piercing member 124. The piercing member 124 can be withdrawn from the pericardial space back into the catheter body 104 in some embodiments. In other embodiments, the thin walled tubular body 140 can be configured (e.g., with sufficient column strength and/or a tapered profile) to be advanced unguided through the TAC. Unguided advancement of the tubular body 140 enables the piercing member 124 to be withdrawn from the pericardial space, e.g., removed from the patient's body, to minimize the time that the piercing member is in the pericardial space. In other embodiments, a separate guide member is exchanged for the piercing member and the guide member is used to advance the tubular body 140.
In one embodiment, the tubular body 140 extends proximally from the apex of the left ventricle across the mitral valve space and into a distal port, e.g., the port 132, of the catheter body 104. The tubular body 140 is configured such that when the blocking member 148 is deployed the tubular body 140 can be placed in tension. When in tension or taut, the tubular body 140 provides a predictable platform for advancing other devices into the mitral valve space.
The catheter body 104 is configured with sufficient stiffness to provide resistance to bending such that withdrawing the catheter body from the position in
A heart valve implant catheter 160 can be advanced over the tubular body 140 after the tubular body 140 is tensioned. The implant catheter 160 can be advanced within a lumen formed in the catheter body 104. In one embodiment, the implant catheter 160 has a registration portion 164 disposed at a distal end thereof. The registration portion 164 can include a length of the implant catheter 160 disposed distal of an implant zone 168 having an implant I thereon. The implant zone 168 can vary from implant to implant, but for a replacement mitral valve, the implant zone 168 can include at least a distal portion in which a ventricular side of a replacement mitral valve is disposed and a proximal portion in which an atrial side of a replacement mitral valve is disposed. A central portion is disposed between the distal and proximal portions. The proximal and distal potions are configured to be disposed over proximal and distal portions of the delivery platform 112. The registration portion 164 can have a length that is approximately equal to the distance from the mitral valve annulus to a registration surface, e.g., ventricular tissue disposed around the internal opening of the TAC.
In one technique, the heart valve implant catheter 160 is advanced over the tubular body 140 into the left atrium. The catheter 160 is further advanced into the left ventricle. Further advancement causes the registration portion 164 of the heart valve implant catheter to contact the left ventricle at the internal opening into the TAC. Such contact can be ascertained by any suitable means, such as by reference to echocardiography or other visualization or by tactile feel. By providing the registration portion 164, the procedure time required for positioning the mitral valve at the correct superior-inferior position can be reduced or minimized.
In one approach, the registration portion 164 is sized or can be selected from a range of catheter having differently sized registration portions 164 to fit the particular patient. For example, echocardiography can be used to ascertain the distance from the plane of the valve annulus to the LV apex. This distance can be used to size or select the appropriate catheter with the appropriately sized registration portion 164. The delivery platform 108 can be deployed as in
The interaction of the registration portion 164 is also illustrated and described below in connection with the embodiment of
In other embodiments, the registration portion 164 can be eliminated. For example, standard visualization techniques can be used to locate radiopaque markers or the implant itself to confirm superior-inferior position.
In addition to superior-inferior position, some implant benefit from proper orientation relative to the plane of the valve annulus. The mitral valve annulus can be approximated by a plane that extends through the inferior-superior mid-point of the zone of attachment of the leaflet to the heart wall of a portion or all aspects of the leaflets. Obtaining the correct attitude of a mitral valve implant I relative to this plane can be accomplished by orienting the tubular body 140 perpendicular to this plane. The tubular body 140 can be so oriented by adjusting the anterior-posterior position of the distal port 132 of the catheter body 104 after the blocking member 148 has been expanded.
While the steering system of
The manner of placing the implant I can vary. In some embodiments, the implant I includes a self-expanding structure, such as a stent body. Such a device may be deployed by retracting a sheath 170 having a distal portion 170A disposed over the implant I prior to deployment. If the registration portion 164 is present, an assembly including the heart valve implant catheter 160 and the sheath 170 are advanced over the delivery platform 112 until the registration portion 164 abuts the heart wall at the LV apex (or a registration member or structure as discussed elsewhere herein). Thereafter, the heart valve implant catheter 160 can be held in position while the sheath 170 is withdrawn. This allows for initial deployment of a distal portion of the implant I. If the positioning is correct, the sheath 170 can be further withdrawn to release a proximal portion of the implant I.
In other embodiments, the heart valve implant catheter 160 is used to expand a support structure of the implant I by applying outward pressure, such as by inflating a balloon upon which the implant I is disposed. In such an embodiment, the sheath 170 can be eliminated or it can remain in place in order to protect the implant I during advancement through the vasculature and/or over the delivery platform 112. The catheter 160 can be modified to have an inflation lumen in fluid communication with a balloon upon which the implant I can be disposed.
In further variations, it is desired to eliminate the TAC. One approach enables the registration portion 164 to provide a stable trajectory between the distal port 132 of the catheter 104 through the mitral valve annulus. This trajectory will be substantially perpendicular to the plane of the annulus or at least within a close range of angles from perpendicular as discussed below. In one approach illustrated in
The expandable member 148A provides some cushioning for the heart wall and preferably also is formed as an inverted cone or angled surface that directs the distal end of the registration portion 164 to the correct position and/or orientation. In one implementation, the expandable member 148A includes a rounded distal tip 306 that is shaped to generally conform to the inside of the left ventricle apex LVA. A distal face 308 of the expandable member 148A is rounded in a way that generally conforms to average shape of the ventricle. The distal face 308 extends from the rounded tip toward a proximal periphery 310. A proximal face 314 of the expandable member 148A is curved inwardly to provide a concave structure or surface. The concave structure of the proximal face 314 preferably has its distal-most portion disposed at the tubular body of the guide member 300. In this way, the implant catheter 160 can be guided to the corrected position and/or orientation beneath the mitral valve. In particular, the implant catheter 160 can be advanced over the body 302 into the concave structure of the expandable member 148A, into close adjacency with the left ventricle apex LVA. The trajectory of the catheter 160 from the distal port 132 to the positioned defined by the concave structure of the expandable member 148A is closely perpendicular to the plane of the mitral valve annulus (or can be adjusted to be so using the steering system discussed above).
In a further variation, the guide member 300 is eliminated and the implant catheter 160 is delivered from the distal port 132 of the catheter 104 into direct contact with the LVA.
Further variants can be provided in which the delivery platform 108 is tensioned but without requiring the TAC to be formed through heart wall. For example,
After the procedure is complete, the tines 148B can be actuated to a removal configuration such that the delivery platform 108 can be withdrawn. In one embodiment, the tines 148B are initially tilted to a position transverse to the longitudinal axis of the delivery platform. The tines 148B engage the wall tissue around the ventricle when the delivery platform 108 is pulled back (e.g., tensioned). In some embodiments, when the delivery platform 108 is in compression the tines 148B disengage from the hear wall. For example, if the tines can be urged a little deeper into the wall of the ventricle the tilt back into alignment with the longitudinal axis of the delivery platform 108 and can be withdrawn proximally from the ventricle wall.
In other embodiments, the tines 148B could be configured to be separated from the rest of the delivery platform 108 so that the tines are left in place but the rest of the delivery platform 108 is easily removed. Various techniques facilitate removal of the delivery platform 108 including torqueing the proximal length of the delivery platform 108 to unscrew a joint adjacent to the tines 148B.
For some patients and for some implants, it is advantageous to prepare at least one of the leaflets prior to placement of the valve. For example, the anterior mitral valve leaflet is flexible but tough. So, its presence between the implant valve and the heart wall from which the leaflet(s) extend can cause a resisting force to the valve structures that are placed over the anterior and/or posterior leaflet. While the mounting structures of the prosthetic valve can be stiffened to overcome the force of the anterior leaflet (and other parts of the natural mitral valve), it may be preferable to mount a less rigid replacement valve in the heart. Heart enlargement is one side effect of congestive heart disease that can reduce valvular sufficiency. Placing overly rigid structures in the rapidly moving heart could add to swelling of the heart or heart damage. For these reasons it would be better to minimize the force applying capability at least of the anterior leaflet.
To this end, the delivery system 100 can include a heart valve procedure catheter 200 independently advanceable from the tubular catheter body 104. The heart valve procedure catheter 200 can be adapted to be positioned for procedures prior to placement of heart valve implant. The procedure catheter 200 can include a distal anchoring zone 204, a proximal advancement and manipulation zone 208 and a procedure zone 212 disposed between the manipulation zone 208 and the anchor zone 204. The procedure zone 212 can have any useful implements to prepare the anterior leaflet and/or can be configured to directly prepare the anterior leaflet.
In one arrangement, the procedure zone 212 has a cutting device 216 disposed thereon that can be brought into contact with the anterior leaflet to segment the leaflet. The cutting device 216 can be one or a plurality of ridges 220 disposed along the length of the procedure zone 212. The procedure catheter 200 can be arranged as discussed in U.S. Pat. No. 8,172,856 to facilitate positioning of the procedure zone 212 along the mitral valve. In some embodiments, the anchor zone 204 provides a fulcrum about which to pivot the procedure zone 212. The pivoting of the procedure zone 212 facilitates placement of the procedure zone along a specific portion of the anterior leaflet. For example, the procedure zone 212 can be placed along a central third of the leaflet by pivoting the manipulation zone 208. A central third of the anterior leaflet is measured as a zone extending one-third of the length of anterior leaflet adjacent to the free edge of the leaflet, where the absolute center of the anterior leaflet at the free edge is within or at the end of the range. Pivoting the manipulation zone 208 can be provided to rotating the proximal end of the procedure catheter 200 about a central axis of the proximal end. In other embodiments, the procedure zone 212 is placed along a central quartile of the anterior leaflet. In some embodiments, the procedure zone 212 is placed within a central half of the anterior leaflet. A central half of the anterior leaflet is measured as fifty percent of the length of anterior leaflet adjacent to the free edge of the leaflet, where the absolute center of the anterior leaflet at the free edge is within or at the end of the range.
While some heart valve placement benefits from segmenting the anterior leaflet or another portion of the mitral valve, some valves can be advantageously placed with the aid of a mere retraction of the leaflet. In one embodiment, the procedure zone 212 is configured to retract the anterior leaflet. For example, the procedure zone 212 of the procedure catheter 200 can be stiffened to prevent the zone 212 from buckling when brought into contact with a portion of the leaflet. The portion contacted can be a central half, one-third or quartile of the leaflet as discussed above. In these embodiments, the procedure zone 212 need not include the ridges 220 for cutting the leaflet, but instead can just include a surface adapted to displace the free edge of the leaflet.
In one variation a retraction portion if provide on one portion of the procedure zone 212 and the ridge 220 or other segmenting portion is provided on another portion of the procedure zone. In these embodiments, the procedure catheter 200 is preferably advanced in an orientation in which the portion desired to interact with the anterior leaflet is on the inside cure of the catheter body when placed. In this context, the inside curve includes the concave or bight forming portion of the procedure zone 212. If the preference is to merely retract, the retraction zone can is positioned on the inside curve and the ridges 220 on the outsides curve (the convex side). If the preference is to merely retract, the ridges are positioned on the inside curve and the retraction zone on the outsides curve.
Placement of the procedure catheter 200 can be achieved by advancing a guide member 260 (e.g., a guidewire) out of a distal port of the catheter body 104. The guide member 260 is delivered through a notch formed between medial and lateral chordae that actuated the anterior leaflet of the mitral valve. The guide wire 260 extends from the notch through the LV outflow tract and the AV into the aorta. Contacting with the anatomy distal the notch (e.g., a wall of the ascending aorta) and the notch causes the retraction zone or the ridges 220 of the procedure catheter 200 to be in a central zone. The central zone can be an anatomical portion the produces bisection of the anterior leaflet or other approximately equal segmentation.
The procedure catheter 200 is positionable based on the anchoring function of the anchor zone 204 and/or the notch between the medial and lateral chordae and in response to torqueing the manipulation zone 208 which can include a proximal portion of the procedure catheter 200 outside the patient. Further details of structures can be used in the procedure catheter 200, such as to position the catheter in a quick yet precise manner are found in U.S. Pat. No. 8,172,856, which is incorporated by reference herein.
Although the present invention has been disclosed with reference to certain specific embodiments of devices and methods, the inventors contemplate that the invention more broadly relates to methods disclosed above, such as those useful for orienting a catheter with respect to an anatomical structure, as well as performing diagnostic and/or therapeutic procedures in the heart or adjacent the heart. Accordingly, the present invention is not intended to be limited to the specific structures and steps disclosed herein, but rather by the full scope of the attached claims.
Number | Name | Date | Kind |
---|---|---|---|
4777951 | Cribier et al. | Oct 1988 | A |
5171259 | Inoue | Dec 1992 | A |
5201880 | Wright et al. | Apr 1993 | A |
5573540 | Yoon | Nov 1996 | A |
5575799 | Bolanos et al. | Nov 1996 | A |
5609598 | Laufer et al. | Mar 1997 | A |
5626588 | Sauer et al. | May 1997 | A |
5716367 | Koike et al. | Feb 1998 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6051014 | Jang | Apr 2000 | A |
6090096 | St. Goar et al. | Jul 2000 | A |
6117144 | Nobles et al. | Sep 2000 | A |
6117145 | Wood et al. | Sep 2000 | A |
6136010 | Modesitt et al. | Oct 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6197043 | Davidson | Mar 2001 | B1 |
6206893 | Klein et al. | Mar 2001 | B1 |
6269819 | Oz et al. | Aug 2001 | B1 |
6287321 | Jang | Sep 2001 | B1 |
6312446 | Huebsch et al. | Nov 2001 | B1 |
6312447 | Grimes | Nov 2001 | B1 |
6325067 | Sterman et al. | Dec 2001 | B1 |
6328757 | Matheny | Dec 2001 | B1 |
6461366 | Seguin | Oct 2002 | B1 |
6508828 | Akerfeldt et al. | Jan 2003 | B1 |
6575971 | Hauck et al. | Jun 2003 | B2 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6752813 | Goldfarb et al. | Jun 2004 | B2 |
6770083 | Seguin | Aug 2004 | B2 |
6926715 | Hauck et al. | Aug 2005 | B1 |
6932792 | St. Goar et al. | Aug 2005 | B1 |
6945978 | Hyde | Sep 2005 | B1 |
7048754 | Martin et al. | May 2006 | B2 |
7226467 | Lucatero et al. | Jun 2007 | B2 |
7563267 | Goldfarb et al. | Jul 2009 | B2 |
7569062 | Kuehn et al. | Aug 2009 | B1 |
7604646 | Goldfarb et al. | Oct 2009 | B2 |
7632308 | Loulmet | Dec 2009 | B2 |
7635329 | Goldfarb et al. | Dec 2009 | B2 |
7666204 | Thornton et al. | Feb 2010 | B2 |
7704269 | St. Goar et al. | Apr 2010 | B2 |
7736388 | Goldfarb et al. | Jun 2010 | B2 |
7811296 | Goldfarb et al. | Oct 2010 | B2 |
7828819 | Webler et al. | Nov 2010 | B2 |
7854762 | Speziali et al. | Dec 2010 | B2 |
7938827 | Hauck et al. | May 2011 | B2 |
7981123 | Seguin | Jul 2011 | B2 |
8123703 | Martin et al. | Feb 2012 | B2 |
8172856 | Eigler et al. | May 2012 | B2 |
8216256 | Raschdorf, Jr. et al. | Jul 2012 | B2 |
8216302 | Wilson et al. | Jul 2012 | B2 |
8303608 | Goldfarb et al. | Nov 2012 | B2 |
8323334 | Deem et al. | Dec 2012 | B2 |
8382796 | Blaeser et al. | Feb 2013 | B2 |
8409219 | Kelley et al. | Apr 2013 | B2 |
8409273 | Thornton et al. | Apr 2013 | B2 |
8545551 | Loulmet | Oct 2013 | B2 |
8568472 | Marchand et al. | Oct 2013 | B2 |
8992605 | Zakai et al. | Mar 2015 | B2 |
9023099 | Duffy et al. | May 2015 | B2 |
9060858 | Thornton et al. | Jun 2015 | B2 |
9474605 | Rowe et al. | Oct 2016 | B2 |
9498330 | Solem | Nov 2016 | B2 |
9763658 | Eigler et al. | Sep 2017 | B2 |
10080657 | Siegel | Sep 2018 | B2 |
10105221 | Siegel | Oct 2018 | B2 |
10499905 | Eigler et al. | Dec 2019 | B2 |
10758265 | Siegel | Sep 2020 | B2 |
20010005787 | Oz et al. | Jun 2001 | A1 |
20020013571 | Goldfarb et al. | Jan 2002 | A1 |
20030120340 | Liska et al. | Jun 2003 | A1 |
20040044350 | Martin et al. | Mar 2004 | A1 |
20040260322 | Rudko et al. | Dec 2004 | A1 |
20050033446 | Deem et al. | Feb 2005 | A1 |
20050107871 | Realyvasquez et al. | May 2005 | A1 |
20050143811 | Realyvasquez | Jun 2005 | A1 |
20050222489 | Randert et al. | Oct 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20060020275 | Goldfarb et al. | Jan 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060229708 | Powell et al. | Oct 2006 | A1 |
20060293739 | Vijay | Dec 2006 | A1 |
20070032850 | Ruiz et al. | Feb 2007 | A1 |
20070038293 | St.Goar et al. | Feb 2007 | A1 |
20070055303 | Vidlund et al. | Mar 2007 | A1 |
20070255273 | Fernandez et al. | Nov 2007 | A1 |
20070270943 | Solem et al. | Nov 2007 | A1 |
20090048668 | Wilson et al. | Feb 2009 | A1 |
20090062836 | Kurrus | Mar 2009 | A1 |
20090076600 | Quinn | Mar 2009 | A1 |
20090177266 | Powell et al. | Jul 2009 | A1 |
20100022823 | Goldfarb et al. | Jan 2010 | A1 |
20100217283 | St.Goar et al. | Aug 2010 | A1 |
20100298929 | Thornton et al. | Nov 2010 | A1 |
20110029071 | Zlotnick et al. | Feb 2011 | A1 |
20110066233 | Thornton et al. | Mar 2011 | A1 |
20110106245 | Miller et al. | May 2011 | A1 |
20110218620 | Meiri et al. | Sep 2011 | A1 |
20110224655 | Asirvatham et al. | Sep 2011 | A1 |
20110264208 | Duffy et al. | Oct 2011 | A1 |
20110313437 | Yeh | Dec 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120010700 | Spenser | Jan 2012 | A1 |
20120065464 | Ellis et al. | Mar 2012 | A1 |
20120078360 | Rafiee | Mar 2012 | A1 |
20120095547 | Chuter | Apr 2012 | A1 |
20120116418 | Belson et al. | May 2012 | A1 |
20120191181 | Kassab et al. | Jul 2012 | A1 |
20120245678 | Solem | Sep 2012 | A1 |
20120310331 | Eigler et al. | Dec 2012 | A1 |
20120310334 | Dolan | Dec 2012 | A1 |
20130018414 | Widimski et al. | Jan 2013 | A1 |
20130030522 | Rowe et al. | Jan 2013 | A1 |
20130197559 | Hariton et al. | Aug 2013 | A1 |
20130226288 | Goldwasser et al. | Aug 2013 | A1 |
20130253547 | Goldfarb et al. | Sep 2013 | A1 |
20130261739 | Kuehn | Oct 2013 | A1 |
20140039607 | Kovach | Feb 2014 | A1 |
20140058502 | Marchand et al. | Feb 2014 | A1 |
20140236198 | Goldfarb et al. | Aug 2014 | A1 |
20140371789 | Hariton | Dec 2014 | A1 |
20150038988 | Tegels et al. | Feb 2015 | A1 |
20150134057 | Rourke et al. | May 2015 | A1 |
20150173765 | Miller et al. | Jun 2015 | A1 |
20160008129 | Siegel | Jan 2016 | A1 |
20160324635 | Vidlund et al. | Nov 2016 | A1 |
20170143478 | Schwartz et al. | May 2017 | A1 |
20170174979 | Sanders | Jun 2017 | A1 |
20170216028 | Khalil | Aug 2017 | A1 |
20170245988 | Siegel et al. | Aug 2017 | A1 |
20170325842 | Siegel et al. | Nov 2017 | A1 |
20180193016 | Eigler et al. | Jul 2018 | A1 |
20180289478 | Quill | Oct 2018 | A1 |
20190008638 | Siegel et al. | Jan 2019 | A1 |
20190298516 | Siegel et al. | Oct 2019 | A1 |
20190365529 | Siegel et al. | Dec 2019 | A1 |
Number | Date | Country |
---|---|---|
106175986 | Dec 2016 | CN |
1 674 040 | Jun 2006 | EP |
1 539 015 | Apr 2011 | EP |
3 269 330 | Jan 2018 | EP |
WO 0060995 | Oct 2000 | WO |
WO 0126557 | Apr 2001 | WO |
WO 01 070116 | Sep 2001 | WO |
WO 02034167 | May 2002 | WO |
WO 03049619 | Jun 2003 | WO |
WO 2004012583 | Feb 2004 | WO |
WO 2005058239 | Jun 2005 | WO |
WO 2007011994 | Jan 2007 | WO |
WO 2011116379 | Sep 2011 | WO |
WO 2014138482 | Sep 2014 | WO |
WO 2016040526 | Mar 2016 | WO |
WO 2016077783 | May 2016 | WO |
WO 2017015632 | Jan 2017 | WO |
WO 2018140535 | Aug 2018 | WO |
WO 2019152598 | Aug 2019 | WO |
Entry |
---|
Bhargava et al., “Biosense Left Ventricular Electromechanical Mapping”, Asian Cardiovasc Thorac Ann 1999, 7:345-52. |
Black MD, M., Division of Pediatric Cardiac Surgery, Standford University School of Medicine, California, USA, Minimally Invasive Pediatric Cardiac Surgery, Online Article in 4 pages. |
Ethicon Wound Closure Manual—Chapter 6, Research and Development at Ethicon, Inc.—An Ongoing Process of Change and Improvement, Online at www.ethiconinc.com in 4 pages. |
Gersak MD, Ph.D., B., “Mitral Valve Repair or Replacement on the Beating Heart”, The Heart Surgery Forum #2000-1989, Jun. 8, 2000, pp. 232-237, 2000 Forum Multimedia Publishing, LLC. |
Perclose A-T, 6F Suture-Mediated Closure (SMC) System, Instructions for Use disctributed in the U.S. by Abbott laboratories, Inc. 2002, 2006 Abbott Laboratories in 11 pages. |
Quealy et al., “Use of Combined Intravascular Ultrasound and PTCA Catheter: Clinical Utility”, Chapter 12, pp. 245-250. |
International Search Report and Written Opinion issued in PCT Application No. PCT/US2014/020867, dated Jun. 23, 2014, in 22 pages. |
International Preliminary Report on Patentability issued in PCT Application No. PCT/US2014/020867, dated Sep. 8, 2015, in 11 pages. |
Number | Date | Country | |
---|---|---|---|
20190076246 A1 | Mar 2019 | US |
Number | Date | Country | |
---|---|---|---|
61774513 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14771704 | US | |
Child | 16128059 | US |